Foghorn Therapeutics, Inc. (FHTX)

In Q1 2026, Foghorn Therapeutics reported a net loss of $19.9 million and decreased collaboration revenue. The company's Q1 2026 revenue missed estimates. As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $183.6 million, partly due to a direct equity and warrant financing in January 2026. The company reported Q4 2025 earnings on March 11, 2026, missing analysts' expectations. Foghorn Therapeutics presented new preclinical data at the 2026 AACR Annual Meeting and participated in several healthcare conferences. As of April 30, 2026, the company had an average recommendation of "Moderate Buy" with an average one-year price target of $11.1250.

Information directly pertaining to the demand seasonality for Foghorn Therapeutics' products and services is not available, as it is a clinical-stage biopharmaceutical company with product candidates still in development. A seasonality analysis of FHTX's stock price indicates that June has the highest probability of positive returns, while May may not be an ideal month to invest.

Foghorn Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines that target genetically determined dependencies within the chromatin regulatory system, particularly for oncology. The company utilizes its Gene Traffic Control platform to identify and validate potential drug targets. Its pipeline includes FHD-909, a selective SMARCA2 inhibitor in Phase 1 trial; a selective CBP degrader (CBPd-171) advancing towards IND-enabling studies; selective EP300 degraders demonstrating superior performance; and first-in-class ARID1B degrader programs.

Foghorn Therapeutics Inc. is headquartered in Watertown, Massachusetts, and was founded in 2015. The company conducts its research and development activities in the United States and collaborates with academic and industry partners.

Foghorn Therapeutics' brand reputation has been influenced by its oncology pipeline progress and analyst sentiment, alongside past challenges. The company has received a "Moderate Buy" recommendation from brokerages and presented preclinical data at scientific conferences. However, past clinical setbacks and financial performance challenges impact its reputation.

Foghorn Therapeutics' stock ownership includes institutional, insider, and retail investors. Institutional shareholders own approximately 74.05% of the company's stock, with major holders including Flagship Pioneering Inc. and Fmr Llc. Insiders own approximately 15.02% of the company's stock, with Cigall Kadoch being the largest individual shareholder. Retail investors own approximately 10.94% of the company.